Wockhardt Stock Soars 19% as USFDA Accepts Historic Drug Application
Wockhardt’s shares surged over 19% to Rs 1,470.90 after the US Food and Drug Administration (USFDA) accepted its New Drug Application (NDA) for the novel antibiotic Zaynich. This marks the first time an Indian pharmaceutical company has had an NDA accepted by the USFDA.
Key Takeaways
- Wockhardt’s stock jumped 19% to Rs 1,470.90 on the BSE.
- The USFDA accepted the New Drug Application (NDA) for antibiotic Zaynich.
- This is a historic first for an Indian pharma company.
- Final approval is expected within 6-9 months via a fast-track process.
A Transformative Milestone for Indian Pharma
The NDA, originally filed on September 30, represents a significant moment for both Wockhardt and the broader Indian pharmaceutical industry. In a regulatory filing, the company highlighted the historic nature of the acceptance.
“The FDA’s acceptance of the Zaynich NDA is a historic and proud moment for the organization and for India. It reaffirms our commitment to developing advanced anti-infective solutions for the world and demonstrates what Indian science and innovation can achieve on the global stage.”
Path to Approval and Market Strategy
Analysts project the formal NDA approval could be granted within the next six to nine months, as Zaynich will be reviewed under a fast-track process. Attention now turns to Wockhardt’s US market strategy, with industry watchers speculating whether the company will pursue a licensing partnership for commercialization.
About the Drug: Zaynich
Zaynich is a first-in-class antibiotic based on a novel β-lactam enhancer mechanism. It has gained international recognition for its potent activity against highly resistant Gram-negative pathogens, which are known to cause prolonged hospital stays and significant global mortality.
